PL369607A1 - Środki naśladujące dysmutazę ponadtlenkową do leczenia zaburzeń i chorób oczu - Google Patents

Środki naśladujące dysmutazę ponadtlenkową do leczenia zaburzeń i chorób oczu

Info

Publication number
PL369607A1
PL369607A1 PL02369607A PL36960702A PL369607A1 PL 369607 A1 PL369607 A1 PL 369607A1 PL 02369607 A PL02369607 A PL 02369607A PL 36960702 A PL36960702 A PL 36960702A PL 369607 A1 PL369607 A1 PL 369607A1
Authority
PL
Poland
Prior art keywords
treatment
diseases
superoxide dismutase
ocular disorders
dismutase mimics
Prior art date
Application number
PL02369607A
Other languages
English (en)
Other versions
PL210225B1 (pl
Inventor
Peter G. Klimko
Robert J.Jr. Collier
Mark R. Hellberg
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of PL369607A1 publication Critical patent/PL369607A1/pl
Publication of PL210225B1 publication Critical patent/PL210225B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL369607A 2001-12-14 2002-12-06 Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu PL210225B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34038901P 2001-12-14 2001-12-14

Publications (2)

Publication Number Publication Date
PL369607A1 true PL369607A1 (pl) 2005-05-02
PL210225B1 PL210225B1 (pl) 2011-12-30

Family

ID=23333158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369607A PL210225B1 (pl) 2001-12-14 2002-12-06 Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu

Country Status (18)

Country Link
US (2) US7759333B2 (pl)
EP (1) EP1463563B1 (pl)
JP (1) JP2005513063A (pl)
KR (1) KR100951606B1 (pl)
CN (2) CN101092432A (pl)
AT (1) ATE422944T1 (pl)
BR (1) BR0214957A (pl)
CA (1) CA2470721C (pl)
CY (1) CY1108983T1 (pl)
DE (1) DE60231246D1 (pl)
DK (1) DK1463563T3 (pl)
ES (1) ES2319399T3 (pl)
MX (1) MXPA04005601A (pl)
PL (1) PL210225B1 (pl)
PT (1) PT1463563E (pl)
SI (1) SI1463563T1 (pl)
WO (1) WO2003051458A1 (pl)
ZA (1) ZA200404435B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
MXPA06006187A (es) * 2003-12-11 2006-08-25 Alcon Inc Imitadores de super oxido dismutasa para el tratamiento de dano retinal y de nervio optico.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
NZ593536A (en) 2008-12-19 2013-07-26 Genentech Inc Quinoline derivatives and methods of use
EP2433640B1 (en) 2010-09-24 2020-01-15 OmniVision GmbH Composition comprising SOD, lutein and zeaxanthin
KR101214364B1 (ko) * 2011-02-15 2012-12-21 한림대학교 산학협력단 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc METHOD FOR THE TREATMENT OF ILLNESSES
KR102531246B1 (ko) * 2021-12-23 2023-05-11 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
WO2023224136A1 (ko) * 2022-05-16 2023-11-23 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
SE9402816D0 (sv) 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
WO1999023097A1 (en) * 1997-11-03 1999-05-14 Duke University Substituted porphyrins
US6291506B1 (en) 1998-08-04 2001-09-18 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Also Published As

Publication number Publication date
CA2470721A1 (en) 2003-06-26
PT1463563E (pt) 2009-03-19
US8003635B2 (en) 2011-08-23
JP2005513063A (ja) 2005-05-12
ATE422944T1 (de) 2009-03-15
CA2470721C (en) 2011-07-12
AU2002351267A1 (en) 2003-06-30
US7759333B2 (en) 2010-07-20
PL210225B1 (pl) 2011-12-30
AU2002351267B2 (en) 2007-04-05
EP1463563A1 (en) 2004-10-06
CY1108983T1 (el) 2014-07-02
EP1463563B1 (en) 2009-02-18
US20050032768A1 (en) 2005-02-10
WO2003051458A1 (en) 2003-06-26
CN1620325A (zh) 2005-05-25
ZA200404435B (en) 2006-05-31
ES2319399T3 (es) 2009-05-07
KR100951606B1 (ko) 2010-04-09
MXPA04005601A (es) 2004-12-06
KR20040063943A (ko) 2004-07-14
HK1069785A1 (en) 2005-06-03
SI1463563T1 (sl) 2009-06-30
US20100204194A1 (en) 2010-08-12
BR0214957A (pt) 2004-12-14
CN101092432A (zh) 2007-12-26
DE60231246D1 (de) 2009-04-02
DK1463563T3 (da) 2009-04-20

Similar Documents

Publication Publication Date Title
WO2004052227A3 (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
WO2006069078A3 (en) Treatment of anal incontinence
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
AU780906C (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
AP1750A (en) Methods for treating ocular neovascular diseases
PL396553A1 (pl) Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
AU2002234806A1 (en) Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
WO2006100677A3 (en) Device and method for pupil size modulation
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MXPA04000124A (es) Composicion farmaceutica para la terapia de cistitis intersticial.
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
BR0017163A (pt) Derivados 5-hidróxi-indazol para tratamento do glaucoma
EP1567166A4 (en) SUPEROXIDE DISMUTASE MIMIC FOR THE TREATMENT OF EYE DISORDER AND DISEASES
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
PT1178819E (pt) Glutationa-redutase para a terapia e profilaxia da sida
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
UA29333A (uk) Очна мазь